Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study

摘要: Background: The goal of antiretroviral therapy (ART) is to suppress viral replication, reduce morbidity and mortality, improve quality life (QoL). For resource-limited settings, the World Health Organization recommends a first-line regimen two-nucleoside reverse-transcriptase inhibitors one non-nucleoside transcriptase inhibitor (nevirapine (NVP) or efavirenz (EFV)). There are few data comparing QoL impact NVP versus EFV. This study assessed change in factors associated with among HIV patients receiving ART regimens based on EFV NVP. Methods: We enrolled 640 people eligible for who received including either was at baseline, three months six using Physical Summary (PHS) Mental (MHS) scores Global Person Generated Index (GPGI). Data were analyzed generalized estimating equations, as primary exposure, identify associations between patient disease QoL. Results: increased ART. mean did not differ significantly during follow-up MHS GPGI regardless CD4 stratum PHS count >250 cells/μL. PHS-adjusted β coefficients by strata follows: �1.61 (95 % CI �2.74, �0.49) 250 corresponding MHS-adjusted �0.39 (�1.40, 0.62) GPGI-adjusted odds ratios 0.51 (0.25, 1.04) improved over 6-month period (MHS p < 0.001; = 0.04, 0.028). Overall, depression (PHS 0.001) had lower women (on NVP, 0.001). Other included alcohol use, low education level advanced disease. Conclusions: improves results support use Patients initiating should be managed appropriately. Women may require extra their